Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising low-cost stocks to buy now. On February 3, Bank of America analyst Jason Zemansky raised the firm’s price target on Syndax to $28 from $27 and kept a Buy rating. Zemansky noted that due to the volume of pre-announcements, upcoming Q4 2025 earnings may not have the same impact as in prior years. Earlier on January 7, Syndax Pharmaceuticals partnered with the World Orphan Drug Alliance to launch a Managed Access Program for Revuforj (revumenib), its first-in-class menin inhibitor. This initiative will provide a pathway for physicians to prescribe the medication to patients in regions where it is not yet commercially available, including parts of Eurasia, Central and Southeast Europe, the Middle East, Israel, Turkey, Latin America, and Africa. The program is designed to operate within local regulatory frameworks and requires secured funding for patients with rare and life-threatening blood cancers. In the US, Revuforj is already FDA-approved for treating adult and pediatric patients with relapsed or refractory acute leukemia involving a KMT2A translocation or NPM1 mutation. These conditions are typically associated with a poor prognosis and limited treatment options. The collaboration aims not only to bridge the current access gap for innovative oncology treatments but also to allow international physicians to gain firsthand clinical experience with the drug.
Photo by National Cancer Institute on Unsplash Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is a commercial-stage biopharmaceutical company that develops therapies for the treatment of cancer. While we acknowledge the potential of SNDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
